Explore This Research Lab


My research is focused on determining the impact of chronic viral infections and cancer on kidney function.

I study the effect of Hepatitis C Virus, Human Immunodeficiency Virus, and COVID-19 on the progression of chronic kidney disease through clinical and translational investigation in patients with these diseases. I am the clinical lead investigator of the MYTHIC trial (NCT03781726) and a co-investigator in the THINKER-NEXT trial (NCT04075916) which transplant Hepatitis C infected kidneys into Hepatitis C uninfected kidney transplant waitlist recipients followed by direct-acting antiviral therapy.

I also study how cancer therapies affect kidney function. Cancer immunotherapies such as immune checkpoint inhibitors and chimeric antigen receptor T cell therapy (CAR-T) have revolutionized cancer therapy, but can cause kidney injury in patients with cancer. Our team uses clinical and translational research studies to uncover risk factors, mechanisms of kidney injury, and best-practices for diagnosis and management of kidney injury in patients receiving cancer immunotherapy. I am an Assistant Professor at Harvard Medical School and the Director of Onconephrology at Massachusetts General Hospital with 75% of my time dedicated to research. I maintain an active clinical presence with 20% clinical and 5% teaching effort.


List of Publications
  1. Sise ME, McQuaid T, Martin P. Sofosbuvir-based hepatitis C therapies in patients with chronic and end-stage kidney disease. Nephrol Dial Transplant. 2021. Epub 2021/04/14. doi: 10.1093/ndt/gfab072. PubMed PMID: 33848334.
  2. Lee MD, Seethapathy H, Strohbehn IA, Zhao SH, Boland GM, Fadden R, Sullivan R, Reynolds KL, Sise ME. Rapid corticosteroid taper versus standard of care for immune checkpoint inhibitor induced nephritis: a single-center retrospective cohort study. J Immunother Cancer. 2021;9(4). Epub 2021/04/15. doi: 10.1136/jitc-2020-002292. PubMed PMID: 33849926; PMCID: PMC8051410.
  3. Molina GE, Zubiri L, Cohen JV, Durbin SM, Petrillo L, Allen IM, Murciano-Goroff YR, Dougan M, Thomas MF, Faje AT, Rengarajan M, Guidon AC, Chen ST, Okin D, Medoff BD, Nasrallah M, Kohler MJ, Schoenfeld SR, Karp Leaf RS, Sise ME, Neilan TG, Zlotoff DA, Farmer JR, Mooradian MJ, Bardia A, Mai M, Sullivan RJ, Semenov YR, Villani AC, Reynolds KL. Temporal Trends and Outcomes Among Patients Admitted for Immune-Related Adverse Events: A Single-Center Retrospective Cohort Study from 2011 to 2018. Oncologist. 2021. Epub 2021/03/04. doi: 10.1002/onco.13740. PubMed PMID: 33655682.
  4. Mathews KS, Soh H, Shaefi S, Wang W, Bose S, Coca S, Gupta S, Hayek SS, Srivastava A, Brenner SK, Radbel J, Green A, Sutherland A, Leonberg-Yoo A, Shehata A, Schenck EJ, Short SAP, Hernan MA, Chan L, Leaf DE, Study of the T, Outcomes in Critically Ill Patients with Coronavirus Disease I. Prone Positioning and Survival in Mechanically Ventilated Patients With Coronavirus Disease 2019-Related Respiratory Failure. Crit Care Med. 2021. Epub 2021/02/18. doi: 10.1097/CCM.0000000000004938. PubMed PMID: 33595960.
  5. Shaefi S, Brenner SK, Gupta S, O'Gara BP, Krajewski ML, Charytan DM, Chaudhry S, Mirza SH, Peev V, Anderson M, Bansal A, Hayek SS, Srivastava A, Mathews KS, Johns TS, Leonberg-Yoo A, Green A, Arunthamakun J, Wille KM, Shaukat T, Singh H, Admon AJ, Semler MW, Hernan MA, Mueller AL, Wang W, Leaf DE, Investigators S-C. Extracorporeal membrane oxygenation in patients with severe respiratory failure from COVID-19. Intensive Care Med. 2021;47(2):208-21. Epub 2021/02/03. doi: 10.1007/s00134-020-06331-9. PubMed PMID: 33528595; PMCID: PMC7851810.
  6. Al-Samkari H, Gupta S, Leaf RK, Wang W, Rosovsky RP, Brenner SK, Hayek SS, Berlin H, Kapoor R, Shaefi S, Melamed ML, Sutherland A, Radbel J, Green A, Garibaldi BT, Srivastava A, Leonberg-Yoo A, Shehata AM, Flythe JE, Rashidi A, Goyal N, Chan L, Mathews KS, Hedayati SS, Dy R, Toth-Manikowski SM, Zhang J, Mallappallil M, Redfern RE, Bansal AD, Short SAP, Vangel MG, Admon AJ, Semler MW, Bauer KA, Hernan MA, Leaf DE, Investigators S-C. Thrombosis, Bleeding, and the Observational Effect of Early Therapeutic Anticoagulation on Survival in Critically Ill Patients With COVID-19. Ann Intern Med. 2021. Epub 2021/01/26. doi: 10.7326/M20-6739. PubMed PMID: 33493012; PMCID: PMC7863679.
  7. Gupta S, Wang W, Hayek SS, Chan L, Mathews KS, Melamed ML, Brenner SK, Leonberg-Yoo A, Schenck EJ, Radbel J, Reiser J, Bansal A, Srivastava A, Zhou Y, Finkel D, Green A, Mallappallil M, Faugno AJ, Zhang J, Velez JCQ, Shaefi S, Parikh CR, Charytan DM, Athavale AM, Friedman AN, Redfern RE, Short SAP, Correa S, Pokharel KK, Admon AJ, Donnelly JP, Gershengorn HB, Douin DJ, Semler MW, Hernan MA, Leaf DE, Investigators S-C. Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19. JAMA Intern Med. 2021;181(1):41-51. Epub 2020/10/21. doi: 10.1001/jamainternmed.2020.6252. PubMed PMID: 33080002; PMCID: PMC7577201.
  8. Seethapathy H, Rusibamayila N, Chute DF, Lee M, Strohbehn I, Zubiri L, Faje AT, Reynolds KL, Jhaveri KD, Sise ME. Hyponatremia and other electrolyte abnormalities in patients receiving immune checkpoint inhibitors. Nephrol Dial Transplant. 2020. Epub 2020/12/30. doi: 10.1093/ndt/gfaa272. PubMed PMID: 33374011.
  9. Murakami N, Mulvaney P, Danesh M, Abudayyeh A, Diab A, Abdel-Wahab N, Abdelrahim M, Khairallah P, Shirazian S, Kukla A, Owoyemi IO, Alhamad T, Husami S, Menon M, Santeusanio A, Blosser CD, Zuniga SC, Soler MJ, Moreso F, Mithani Z, Ortiz-Melo D, Jaimes EA, Gutgarts V, Lum E, Danovitch GM, Cardarelli F, Drews RE, Bassil C, Swank JL, Westphal S, Mannon RB, Shirai K, Kitchlu A, Ong S, Machado SM, Mothi SS, Ott PA, Rahma O, Hodi FS, Sise ME, Gupta S, Leaf DE, Devoe CE, Wanchoo R, Nair VV, Schmults CD, Hanna GJ, Sprangers B, Riella LV, Jhaveri KD, Immune Checkpoint Inhibitors in Solid Organ Transplant C. A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant. Kidney Int. 2020. Epub 2020/12/29. doi: 10.1016/j.kint.2020.12.015. PubMed PMID: 33359528.
  10. Seethapathy H, Lee MD, Strohbehn IA, Efe O, Rusibamayila N, Chute DF, Colvin RB, Rosales IA, Fadden RM, Reynolds KL, Sullivan RJ, Kaufman HL, Jhaveri KD, Sise ME. Clinical features of acute kidney injury in patients receiving dabrafenib and trametinib. Nephrol Dial Transplant. 2020. Epub 2020/12/24. doi: 10.1093/ndt/gfaa372. PubMed PMID: 33355659.
  11. Estiverne C, Strohbehn IA, Mithani Z, Hirsch JS, Wanchoo R, Goyal PG, Lee Dryden-Peterson S, Pearson JC, Kubiak DW, Letourneau AR, Bhattacharyya R, Jhaveri KD, Sise ME. Remdesivir in Patients With Estimated GFR <30 ml/min per 1.73 m(2) or on Renal Replacement Therapy. Kidney Int Rep. 2021;6(3):835-8. Epub 2020/12/03. doi: 10.1016/j.ekir.2020.11.025. PubMed PMID: 33263094; PMCID: PMC7694470.
  12. Gupta S, Hayek SS, Wang W, Chan L, Mathews KS, Melamed ML, Brenner SK, Leonberg-Yoo A, Schenck EJ, Radbel J, Reiser J, Bansal A, Srivastava A, Zhou Y, Sutherland A, Green A, Shehata AM, Goyal N, Vijayan A, Velez JCQ, Shaefi S, Parikh CR, Arunthamakun J, Athavale AM, Friedman AN, Short SAP, Kibbelaar ZA, Abu Omar S, Admon AJ, Donnelly JP, Gershengorn HB, Hernan MA, Semler MW, Leaf DE, Investigators S-C. Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US. JAMA Intern Med. 2020;180(11):1436-47. Epub 2020/07/16. doi: 10.1001/jamainternmed.2020.3596. PubMed PMID: 32667668; PMCID: PMC7364338.
  13. Nguyen T, Sise ME, Delgado C, Williams W, Reese P, Goldberg D. Race, Education, and Gender Disparities in Transplantation of Kidneys from Hepatitis C Viremic Donors. Transplantation. 2020. Epub 2020/11/04. doi: 10.1097/TP.0000000000003511. PubMed PMID: 33141804.
  14. Lee MD, Strohbehn IA, Seethapathy HS, Rusibamayila N, Casey KS, Gupta S, Leaf DE, Frigault MJ, Sise ME. Acute Kidney Injury After the CAR-T Therapy Tisagenlecleucel. Am J Kidney Dis. 2020. Epub 2020/10/26. doi: 10.1053/j.ajkd.2020.08.017. PubMed PMID: 33098925; PMCID: PMC8060348.
  15. Chewcharat A, Chang YT, Sise ME, Bhattacharyya RP, Murray MB, Nigwekar SU. Phase-3 Randomized Controlled Trials on Exclusion of Participants With Kidney Disease in COVID-19. Kidney Int Rep. 2021;6(1):196-9. Epub 2020/10/28. doi: 10.1016/j.ekir.2020.10.010. PubMed PMID: 33106779; PMCID: PMC7577277.
  16. Gupta S, Coca SG, Chan L, Melamed ML, Brenner SK, Hayek SS, Sutherland A, Puri S, Srivastava A, Leonberg-Yoo A, Shehata AM, Flythe JE, Rashidi A, Schenck EJ, Goyal N, Hedayati SS, Dy R, Bansal A, Athavale A, Nguyen HB, Vijayan A, Charytan DM, Schulze CE, Joo MJ, Friedman AN, Zhang J, Sosa MA, Judd E, Velez JCQ, Mallappallil M, Redfern RE, Bansal AD, Neyra JA, Liu KD, Renaghan AD, Christov M, Molnar MZ, Sharma S, Kamal O, Boateng JO, Short SAP, Admon AJ, Sise ME, Wang W, Parikh CR, Leaf DE, Investigators S-C. AKI Treated with Renal Replacement Therapy in Critically Ill Patients with COVID-19. J Am Soc Nephrol. 2021;32(1):161-76. Epub 2020/10/18. doi: 10.1681/ASN.2020060897. PubMed PMID: 33067383; PMCID: PMC7894677.
  17. Endres P, Rosovsky R, Zhao S, Krinsky S, Percy S, Kamal O, Roberts RJ, Lopez N, Sise ME, Steele DJR, Lundquist AL, Rhee EP, Hibbert KA, Hardin CC, Mc Causland FR, Czarnecki PG, Mutter W, Tolkoff-Rubin N, Allegretti AS. Filter clotting with continuous renal replacement therapy in COVID-19. J Thromb Thrombolysis. 2021;51(4):966-70. Epub 2020/10/08. doi: 10.1007/s11239-020-02301-6. PubMed PMID: 33026569; PMCID: PMC7539277.
  18. Hayek SS, Brenner SK, Azam TU, Shadid HR, Anderson E, Berlin H, Pan M, Meloche C, Feroz R, O'Hayer P, Kaakati R, Bitar A, Padalia K, Perry D, Blakely P, Gupta S, Shaefi S, Srivastava A, Charytan DM, Bansal A, Mallappallil M, Melamed ML, Shehata AM, Sunderram J, Mathews KS, Sutherland AK, Nallamothu BK, Leaf DE, Investigators S-C. In-hospital cardiac arrest in critically ill patients with covid-19: multicenter cohort study. BMJ. 2020;371:m3513. Epub 2020/10/02. doi: 10.1136/bmj.m3513. PubMed PMID: 32998872.
  19. Flythe JE, Assimon MM, Tugman MJ, Chang EH, Gupta S, Shah J, Sosa MA, Renaghan AD, Melamed ML, Wilson FP, Neyra JA, Rashidi A, Boyle SM, Anand S, Christov M, Thomas LF, Edmonston D, Leaf DE, Investigators S-C. Characteristics and Outcomes of Individuals With Pre-existing Kidney Disease and COVID-19 Admitted to Intensive Care Units in the United States. Am J Kidney Dis. 2021;77(2):190-203 e1. Epub 2020/09/23. doi: 10.1053/j.ajkd.2020.09.003. PubMed PMID: 32961244; PMCID: PMC7501875.
  20. Molnar MZ, Bhalla A, Azhar A, Tsujita M, Talwar M, Balaraman V, Sodhi A, Kadaria D, Eason JD, Hayek SS, Coca SG, Shaefi S, Neyra JA, Gupta S, Leaf DE, Kovesdy CP, Investigators S-C. Outcomes of critically ill solid organ transplant patients with COVID-19 in the United States. Am J Transplant. 2020;20(11):3061-71. Epub 2020/08/28. doi: 10.1111/ajt.16280. PubMed PMID: 32844546; PMCID: PMC7460925.
  21. Ng JH, Bijol V, Sparks MA, Sise ME, Izzedine H, Jhaveri KD. Pathophysiology and Pathology of Acute Kidney Injury in Patients With COVID-19. Adv Chronic Kidney Dis. 2020;27(5):365-76. Epub 2020/12/15. doi: 10.1053/j.ackd.2020.09.003. PubMed PMID: 33308501; PMCID: PMC7574722.
  22. Sise ME, Goldberg DS, Kort JJ, Schaubel DE, Alloway RR, Durand CM, Fontana RJ, Brown RS, Jr., Friedewald JJ, Prenner S, Landis JR, Fernando M, Phillips CC, Woodle ES, Rike-Shields A, Sherman KE, Elias N, Williams WW, Gustafson JL, Desai NM, Barnaba B, Norman SP, Doshi M, Sultan ST, Aull MJ, Levitsky J, Belshe DS, Chung RT, Reese PP. Multicenter Study to Transplant Hepatitis C-Infected Kidneys (MYTHIC): An Open-Label Study of Combined Glecaprevir and Pibrentasvir to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus Infection. J Am Soc Nephrol. 2020;31(11):2678-87. Epub 2020/08/28. doi: 10.1681/ASN.2020050686. PubMed PMID: 32843477; PMCID: PMC7608971.
  23. Seethapathy H, Zhao S, Strohbehn IA, Lee M, Chute DF, Bates H, Molina GE, Zubiri L, Gupta S, Motwani S, Leaf DE, Sullivan RJ, Rahma O, Blumenthal KG, Villani AC, Reynolds KL, Sise ME. Incidence and clinical features of immune-related acute kidney injury in patients receiving Programmed Cell Death Ligand-1 Inhibitors. KI Reports. 2020. Epub 2020/07/20. doi: 10.1016/j.ekir.2020.07.011
  24. Johnson DB, Jakubovic BD, Sibaud V, Sise ME. Balancing cancer immunotherapy efficacy and toxicity. J Allergy Clin Immunol Pract. 2020. Epub 2020/07/01. doi: 10.1016/j.jaip.2020.06.028. PubMed PMID: 32599218.
  25. Adamsick ML, Gandhi RG, Bidell MR, Elshaboury RH, Bhattacharyya RP, Kim AY, Nigwekar S, Rhee EP, Sise ME. Remdesivir in Patients with Acute or Chronic Kidney Disease and COVID-19. J Am Soc Nephrol. 2020;31(7):1384-6. Epub 2020/06/10. doi: 10.1681/ASN.2020050589. PubMed PMID: 32513665; PMCID: PMC7351006.
  26. Strohbehn IA, Lee M, Seethapathy H, Chute D, Rhama O, Guidon A, Neilan TG, Zlotoff DA, Okin D, Rengarajan M, Reynolds K, Sise ME. Safety and Efficacy of Immune Checkpoint Inhibitors in Patients on Dialysis: A Retrospective Case Series. Am J Kidney Dis. 2020. Epub 2020/05/18. doi: 10.1053/j.ajkd.2020.02.451. PubMed PMID: 32417401.
  27. Sise ME, Strohbehn I, Chute D, Corey KE, Fusco DN, Sabbisetti VS, Waikar SS, Chung RT. Low Complement C4 Predicts Improvement of Kidney Function After Direct-Acting Antiviral Therapy for Hepatitis C Virus. Hepatol Commun. 2020;4(8):1206-17. Epub 2020/08/09. doi: 10.1002/hep4.1528. PubMed PMID: 32766479; PMCID: PMC7395066.
  28. Sise ME, Baggett MV, Shepard JO, Stevens JS, Rhee EP. Case 17-2020: A 68-Year-Old Man with Covid-19 and Acute Kidney Injury. N Engl J Med. 2020;382(22):2147-56. Epub 2020/05/14. doi: 10.1056/NEJMcpc2002418. PubMed PMID: 32402156; PMCID: PMC7959270.
  29. Seethapathy H, Bates H, Chute DF, Strohbehn I, Strohbehn S, Fadden RM, Reynolds KL, Cohen JV, Sullivan RJ, Sise ME. Acute Kidney Injury Following Encorafenib and Binimetinib for Metastatic Melanoma. Kidney Med. 2020;2(3):373-5. Epub 2020/08/01. doi: 10.1016/j.xkme.2020.01.012. PubMed PMID: 32734258; PMCID: PMC7380350.
  30. Reddy YNV, Reddy KP, Sise ME. HCV-Infected Deceased Donor Kidney Transplantation-Time to Take Up the Offer. Am J Kidney Dis. 2020;75(6):827-9. Epub 2020/04/23. doi: 10.1053/j.ajkd.2020.01.010. PubMed PMID: 32317120; PMCID: PMC7247921.
  31. Strohbehn S, Seethapathy H, Rusibamayila N, Strohbehn I, Lee M, Hobbs G, Keyzner A, Jhaveri KD, Sise ME. Acute kidney injury after ruxolitinib: Common complication, uncommon cause. Am J Hematol. 2020. Epub 2020/04/03. doi: 10.1002/ajh.25804. PubMed PMID: 32239674.
  32. Roth D, Bloom RD, Molnar MZ, Reese PP, Sawinski D, Sise ME, Terrault NA. KDOQI US Commentary on the 2018 KDIGO Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C. Am J Kidney Dis. 2020;75(5):665-83. Epub 2020/04/14. doi: 10.1053/j.ajkd.2019.12.016. PubMed PMID: 32279907.
  33. Bethea E, Arvind A, Gustafson J, Andersson K, Pratt D, Bhan I, Thiim M, Corey K, Bloom P, Markmann J, Yeh H, Elias N, Kimura S, Dageforde LA, Cuenca A, Kawai T, Safa K, Williams W, Gilligan H, Sise M, Fishman J, Kotton C, Kim A, Rogers CC, Shao S, Cote M, Irwin L, Myoung P, Chung RT. Immediate administration of antiviral therapy after transplantation of hepatitis C-infected livers into uninfected recipients: Implications for therapeutic planning. Am J Transplant. 2020;20(6):1619-28. Epub 2019/12/31. doi: 10.1111/ajt.15768. PubMed PMID: 31887236; PMCID: PMC8005111.
  34. Gupta S, Seethapathy H, Strohbehn IA, Frigault MJ, O’Donnell EK, Jacobson CA, Motwani SS, Parikh SM, Curhan GC, Reynolds KL, Leaf DE, Sise ME. Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma. Am J Kidney Dis. 2020. Epub 2020/01/25. doi: 10.1053/j.ajkd.2019.10.011. PubMed PMID: 31973908.
  35. Sise ME, Strohbehn IA, Chute DF, Gustafson J, Van Deerlin VM, Smith JR, Gentile C, Wojciechowski D, Williams WW, Elias N, Chung RT. Preemptive Treatment With Elbasvir and Grazoprevir for Hepatitis C-Viremic Donor to Uninfected Recipient Kidney Transplantation. Kidney Int Rep. 2020;5(4):459-67. Epub 2020/04/14. doi: 10.1016/j.ekir.2020.01.001. PubMed PMID: 32280841; PMCID: PMC7136432.
  36. Cortazar FB, Kibbelaar ZA, Glezerman IG, Abudayyeh A, Mamlouk O, Motwani SS, Murakami N, Herrmann SM, Manohar S, Shirali AC, Kitchlu A, Shirazian S, Assal A, Vijayan A, Renaghan AD, Ortiz-Melo DI, Rangarajan S, Malik AB, Hogan JJ, Dinh AR, Shin DS, Marrone KA, Mithani Z, Johnson DB, Hosseini A, Uprety D, Sharma S, Gupta S, Reynolds KL, Sise ME, Leaf DE. Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study. J Am Soc Nephrol. 2020;31(2):435-46. Epub 2020/01/04. doi: 10.1681/ASN.2019070676. PubMed PMID: 31896554.
  37. Lawitz E, Flisiak R, Abunimeh M, Sise ME,Park JY, Kaskas M, Bruchfeld A, Worns MA, Aglitti A, Zamor PJ, Xue Z, Schnell G, Jalundhwala YJ, Porcalla A, Mensa FJ, Persico M. Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection. Liver Int. 2020;40(5):1032-41. Epub 2019/12/11. doi: 10.1111/liv.14320. PubMed PMID: 31821716.
  38. McMahon GM, Amodu A, Sise ME, Mothi SS, Palsson R, Waikar SS. Physician Attitudes on Kidney Biopsies for Research: A Survey Study. Kidney Med. 2020;2(1):82-4. Epub 2020/08/01. doi: 10.1016/j.xkme.2019.10.009. PubMed PMID: 32734230; PMCID: PMC7380349.
  39. Qualls D, Seethapathy H, Bates H, Tajmir S, Heidari P, Endres P, Reynolds K, Lawrence D, Sise M. Positron emission tomography as an adjuvant diagnostic test in the evaluation of checkpoint inhibitor-associated acute interstitial nephritis. J Immunother Cancer. 2019;7(1):356. Epub 2019/12/23. doi: 10.1186/s40425-019-0820-9. PubMed PMID: 31864416.
  40. Zubiri L, Allen IM, Taylor MS, Guidon AC, Chen ST, Schoenfeld SR, Neilan TG, Sise ME, Mooradian MJ, Rubin KM, Leaf RK, Parikh AR, Faje A, Gainor JF, Cohen JV, Fintelmann FJ, Kohler MJ, Dougan M, Reynolds KL. Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy. Oncologist. 2020;25(3):e398-e404. Epub 2020/03/13. doi: 10.1634/theoncologist.2018-0883. PubMed PMID: 32162817.
  41. Potluri VS, Goldberg DS, Mohan S, Bloom RD, Sawinski D, Abt PL, Blumberg EA, Parikh CR, Sharpe J, Reddy KR, Molnar MZ, Sise M, Reese PP. National Trends in Utilization and 1-Year Outcomes with Transplantation of HCV-Viremic Kidneys. J Am Soc Nephrol. 2019;30(10):1939-51. Epub 2019/09/14. doi: 10.1681/ASN.2019050462. PubMed PMID: 31515244; PMCID: PMC6779360.
  42. Seethapathy H, Zhao S, Chute DF, Zubiri L, Oppong Y, Strohbehn I, Cortazar FB, Leaf DE, Mooradian MJ, Villani AC, Sullivan RJ, Reynolds K, Sise ME. The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors. Clin J Am Soc Nephrol. 2019;14(12):1692-700. Epub 2019/11/02. doi: 10.2215/CJN.00990119. PubMed PMID: 31672794.
  43. Sise ME,Strohbehn IA, Bethea E, Gustafson JL, Chung RT. Balancing the risk and rewards of utilizing organs from hepatitis C viremic donors. Curr Opin Organ Transplant. 2019;24(3):351-7. Epub 2019/05/16. doi: 10.1097/MOT.0000000000000651. PubMed PMID: 31090648; PMCID: PMC7093034.
  44. Sise ME,Wojciechowski D, Chute DF, Gustafson J, Chung RT, Williams WW, Elias N. Process of selecting and educating HCV-uninfected kidney waiting-list candidates for HCV-infected kidney transplantation. Artif Organs. 2019;43(9):913-20. Epub 2019/04/20. doi: 10.1111/aor.13473. PubMed PMID: 31001828; PMCID: PMC6733639.
  45. Sise ME, Chute DF, Oppong Y, Davis MI, Long JD, Silva ST, Rusibamayila N, Jean-Francois D, Raji S, Zhao S, Thadhani R, Chung RT. Direct-acting antiviral therapy slows kidney function decline in patients with Hepatitis C virus infection and chronic kidney disease. Kidney Int. 2020;97(1):193-201. Epub 2019/07/25. doi: 10.1016/j.kint.2019.04.030. PubMed PMID: 31337501; PMCID: PMC7094798.
  46. Sise ME, Seethapathy H, Reynolds KL. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Renal Toxicity: Illustrative Case and Review. Oncologist. 2019;24(6):735-42. Epub 2019/03/25. doi: 10.1634/theoncologist.2018-0764. PubMed PMID: 30902916.
  47. Sise ME.Safety and Efficacy of Paritaprevir/Ritonavir, Ombitasvir, and Dasabuvir for Hepatitis C Virus Infection Across All Levels of Kidney Function. Kidney Int Rep. 2019;4(2):191-3. Epub 2019/02/19. doi: 10.1016/j.ekir.2018.11.018. PubMed PMID: 30775615; PMCID: PMC6365390.
  48. Henson JB, Sise ME. The association of hepatitis C infection with the onset of CKD and progression into ESRD. Semin Dial. 2019;32(2):108-18. Epub 2018/11/30. doi: 10.1111/sdi.12759. PubMed PMID: 30496620; PMCID: PMC6410728.
  49. Bomback AS, Sise ME. A Three-Headed Approach to Kidney Involvement in Rheumatic Diseases. Rheum Dis Clin North Am. 2018;44(4):xiii-xiv. Epub 2018/10/03. doi: 10.1016/j.rdc.2018.08.001. PubMed PMID: 30274633.
  50. Long JD, Rutledge SM, Sise ME. Autoimmune Kidney Diseases Associated with Chronic Viral Infections. Rheum Dis Clin North Am. 2018;44(4):675-98. Epub 2018/10/03. doi: 10.1016/j.rdc.2018.06.006. PubMed PMID: 30274630.
  51. Sise ME. Hepatitis C virus infection and the kidney. Nephrol Dial Transplant. 2018. Epub 2018/07/31. doi: 10.1093/ndt/gfy230. PubMed PMID: 30060216; PMCID: PMC6399482.
  52. Rutledge SM, Chung RT, Sise ME. Treatment of hepatitis C virus infection in patients with mixed cryoglobulinemic syndrome and cryoglobulinemic glomerulonephritis. Hemodial Int. 2018;22 Suppl 1:S81-S96. Epub 2018/04/26. doi: 10.1111/hdi.12649. PubMed PMID: 29694729.
  53. Sise ME, Chute DF, Gustafson JL, Wojciechowski D, Elias N, Chung RT, Williams WW. Transplantation of hepatitis C virus infected kidneys into hepatitis C virus uninfected recipients. Hemodial Int. 2018;22 Suppl 1:S71-S80. Epub 2018/04/26. doi: 10.1111/hdi.12650. PubMed PMID: 29694722.
  54. Chute DF, Chung RT, Sise ME. Direct-acting antiviral therapy for hepatitis C virus infection in the kidney transplant recipient. Kidney Int. 2018;93(3):560-7. Epub 2018/01/13. doi: 10.1016/j.kint.2017.10.024. PubMed PMID: 29325996.
  55. Chute DF, Sise ME. Effect of the Opioid Crisis on the Donor Pool for Kidney Transplantation: An Analysis of National Kidney Deceased Donor Trends from 2010-2016. Am J Nephrol. 2018;47(2):84-93. Epub 2018/02/14. doi: 10.1159/000486516. PubMed PMID: 29439266.
  56. Parikh A, Rizzo JA, Canetta P, Forster C, Sise M, Maarouf O, Singer E, Elger A, Elitok S, Schmidt-Ott K, Barasch J, Nickolas TL. Correction: Does NGAL reduce costs? A cost analysis of urine NGAL (uNGAL) & serum creatinine (sCr) for acute kidney injury (AKI) diagnosis. PLoS One. 2017;12(9):e0185772. Epub 2017/09/28. doi: 10.1371/journal.pone.0185772. PubMed PMID: 28953968; PMCID: PMC5617218.
  57. Davis MI, Chute DF, Chung RT, Sise ME. When and how can nephrologists treat hepatitis C virus infection in dialysis patients? Semin Dial. 2018;31(1):26-36. Epub 2017/09/20. doi: 10.1111/sdi.12650. PubMed PMID: 28925068.
  58. Sise ME, Backman E, Ortiz GA, Hundemer GL, Ufere NN, Chute DF, Brancale J, Xu D, Wisocky J, Lin MV, Kim AY, Thadhani R, Chung RT. Effect of Sofosbuvir-Based Hepatitis C Virus Therapy on Kidney Function in Patients with CKD. Clin J Am Soc Nephrol. 2017;12(10):1615-23. Epub 2017/09/09. doi: 10.2215/CJN.02510317. PubMed PMID: 28882857; PMCID: PMC5628711.
  59. Sise ME. Kidney transplant recipients with hepatitis C virus experienced 100% sustained virologic response at 12 weeks when treated with sofosbuvir-ledipasvir. Hepatology. 2017;66(4):1335-7. Epub 2017/06/27. doi: 10.1002/hep.29339. PubMed PMID: 28650558.
  60. Parikh A, Rizzo JA, Canetta P, Forster C, Sise M, Maarouf O, Singer E, Elger A, Elitok S, Schmidt-Ott K, Barasch J, Nickolas TL. Does NGAL reduce costs? A cost analysis of urine NGAL (uNGAL) & serum creatinine (sCr) for acute kidney injury (AKI) diagnosis. PLoS One. 2017;12(5):e0178091. Epub 2017/05/26. doi: 10.1371/journal.pone.0178091. PubMed PMID: 28542336; PMCID: PMC5438176.
  61. Hogan JJ, Lim MA, Palmer MB, Bloom RD, Chung RT, Sise ME. Development of proteinuria and focal segmental glomerulosclerosis during direct-acting antiviral therapy for hepatitis C virus infection. Hepatology. 2017;66(2):658-60. Epub 2017/02/18. doi: 10.1002/hep.29125. PubMed PMID: 28211090.
  62. Sise ME, Lo GC, Goldstein RH, Allegretti AS, Masia R. Case 12-2017 - A 34-Year-Old Man with Nephropathy. N Engl J Med. 2017;376(16):1575-85. Epub 2017/04/20. doi: 10.1056/NEJMcpc1616395. PubMed PMID: 28423292.
  63. Sise ME, Wisocky J, Rosales IA, Chute D, Holmes JA, Corapi KM, Babitt JL, Tangren JS, Hashemi N, Lundquist AL, Williams WW, Mount DB, Andersson KL, Rennke HG, Smith RN, Colvin R, Thadhani RI, Chung RT. Lupus-like Immune Complex-mediated Glomerulonephritis in Patients with Hepatitis C Virus Infection Treated with Oral, Interferon-free, Direct-acting Antiviral Therapy. Kidney Int Rep. 2016;1(3):135-43. Epub 2016/12/19. doi: 10.1016/j.ekir.2016.06.006. PubMed PMID: 27990496; PMCID: PMC5155703.
  64. Lin MV, Sise ME, Pavlakis M, Amundsen BM, Chute D, Rutherford AE, Chung RT, Curry MP, Hanifi JM, Gabardi S, Chandraker A, Heher EC, Elias N, Riella LV. Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection. PLoS One. 2016;11(7):e0158431. Epub 2016/07/16. doi: 10.1371/journal.pone.0158431. PubMed PMID: 27415632; PMCID: PMC4945034.
  65. Saxena V, Koraishy FM, Sise ME, Lim JK, Schmidt M, Chung RT, Liapakis A, Nelson DR, Fried MW, Terrault NA, Hcv T. Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function. Liver Int. 2016;36(6):807-16. Epub 2016/03/01. doi: 10.1111/liv.13102. PubMed PMID: 26923436; PMCID: PMC6453817.
  66. Sise ME, Bloom AK, Wisocky J, Lin MV, Gustafson JL, Lundquist A, Steele D, Thiim M, William WW, Hashemi N, Kim AY, Thadhani R, Chung RT. “Treatment of Hepatitis C Virus-Associated Mixed Cryoglobulinemia with Direct Antiviral Agents” Hepatology. 2016; 63(2):408-17
  67. Hundemer GL*, Sise ME* (*equal contribution), Wiscoky J, Ufere N, Friedman LS, Corey KE, Chung RT. “Use of Sofosbuvir-Based Direct-Acting Antiviral Therapy for Hepatitis C Viral Infection in Patients with Severe Renal Insufficiency.” Infect Dis. 2015; 47(12):924-9
  68. Sise ME, Backman ES, Wenger JB, Wood BR, Sax PE, Chung RT, Thadhani R, Kim AY. “Short and Long-term Effects of Telaprevir on Kidney Function in Patients with Hepatitis C Virus Infeciton: A Retrospective Cohort Study.” PLoS One. 2015; 10(4):e0124139
  69. Sise ME, Hirsch JS, Canetta PA, Herlitz L, Mohan S. Nonalbumin proteinuria predominates in biopsy-proven tenofovir nephrotoxicity. AIDS. 2015; 29(8):941-6.
  70. Connors NJ, Sise ME, Nelson LS, Hoffman RS, Smith SW. Methotrexate toxicity treated with continuous venovenous hemofiltration, leucovorinand glucarpidase. Clin Kidney J. 2014; 7(6):590-2.
  71. Strazzula L, Nigwekar SU, Steele D, Tsiaras W, Sise M, Bis S, Smith GP, Kroshinsky D. Intralesional sodium thiosulfate for the treatment of calciphylaxis. JAMA Dermatol. 2013; 149(8):946-9
  72. Sise ME, Courtwright A, Channick R. Pulmonary Hypertension in patients with chronic and end-stage kidney disease. Kidney Int. 2013; 84(4):682-92
  73. Sise ME, Parravicini E, Barasch J. Urinary neutrophil gelatinase associated lipocalin identifies neonates with high probability of sepsis. Pediatrics. 2012; 130(4):e1053
  74. Nickolas TL, Forster CS, Sise ME, Barasch N, Solá-Del Valle D, Viltard M, Buchen C, Kupferman S, Carnevali ML, Bennett M, Mattei S, Bovino A, Argentiero L, Magnano A, Devarajan P, Mori K, Erdjument-Bromage H, Tempst P, Allegri L, Barasch J. NGAL (Lcn2) monomer is associated with tubulointerstitial damage in chronic kidney disease. Kidney Int. 2012; 82(6): 718-22.
  75. Verna EC, Brown RS, Farrand E, Pichardo EM, Forster CS, Sola-Del Valle DA, Adkins SH, Sise ME, Oliver JA, Radhakrishnan J, Barasch JM, Nickolas TL. ‘Urinary Neutrophil Gelatinase-Associated Lipocalin Predicts Mortality and Identifies Acute Kidney Injury In Cirrhosis.Dig Dis Sci. 2012; 57(9):2362-70.
  76. Nickolas TL, Schmidt-Ott KM, Canetta P, Forster C, Singer E, Sise M, Elger A, Maarouf O, Sola-Del Valle DA, O'Rourke M, Sherman E, Lee P, Geara A, Imus P, Guddati A, Polland A, Rahman W, Elitok S, Malik N, Giglio J, El-Sayegh S, Devarajan P, Hebbar S, Saggi SJ, Hahn B, Kettritz R, Luft FC, Barasch J. “Diagnostic and Prognostic Stratification in the Emergency Department with Urinary Biomarkers of Nephron Damage: A Multicenter Prospective Cohort Study” J Am Coll Cardiol. 2012; 59(3):246-255.
  77. Sise ME, Forster C, Singer E, Sola-Del Valle D, Hahn B, Schmidt-Ott K, Barasch J, Nickolas TL. “Urine Neutrophil Gelatinase Associated Lipocalin Identifies Unilateral and Bilateral Urinary Tract Obstruction.” Nephrol Dial Transplant. 2011 Dec;26(12):4132-4135.
  78. Sola-Del Valle D, Mohan S, TseChen J, Paragas NA, Sise ME, D’Agati V, Barasch JM. "Urinary NGAL is a useful clinical biomarker of HIV-associated nephropathy. Nephrol Dial Transplant. 2011; 26(7):2387-2390.
  79. Parravicini E, Nemerofsky SL, Michelson KA, Huynh TK, Sise ME, Bateman DA, Lorenz JM, Barasch JM. Urinary neutrophil gelatinase-associated lipocalin is a promising biomarker for late onset culture-positive sepsis in very low birth weight infants. Pediatr Res. 2010; 67(6):636-640.
  80. Huynh TK, Bateman DA, Parravicini E, Lorenz JM, Nemerofsky SL, Sise ME, Bowman TM, Polesana E, Barasch JM. Reference values of urinary neutrophil gelatinase-associated lipocalin in very low birth weight infants. Pediatr Res. 200; 66(5):528-532.
  81. Paragas N, Nickolas TL, Wyatt C, Forster CS, Sise M, Morgello S, Jagla B, Buchen C, Stella P, Sanna-Cherchi S, Carnevali ML, Mattei S, Bovino A, Argentiero L, Magnano A, Devarajan P, Schmidt-Ott KM, Allegri L, Klotman P, D'Agati V, Gharavi AG, Barasch J. Urinary NGAL marks cystic disease in HIV-associated nephropathy. J Am Soc Nephrol. 2009; 20(8):1687-1692
  82. Sise ME, Barasch J, Devarajan P, Nickolas TL. Elevated urine Neutrophil Gelatinase-Associated Lipocalin can predict Acute on Chronic Kidney Disease. Kidney Int. 2009; 75(1):115-116
  83. Nickolas TL, O’Rourke MJ, Yang J, Sise ME, Canetta PA, Barasch N, Buchen C, Khan F, Mori K, Giglio J, Devarajan P, Barasch J. Sensitivity and specificity of a single emergency department measurement of urinary Neutrophil gelatinase-associated lipocalin for diagnosing acute kidney injury. Ann Intern Med. 2008; 148(11):810-819